Health
Insurers Say They ‘Can’t Afford’ Ozempic and Zepbound. What the Data on Healthier Patients and Cost Savings Actually Shows.
Insurers say the new weight-loss drugs are unaffordable. The data on healthier patients tells a more complicated story.
Section
Health
11 stories
Health
Insurers Say They ‘Can’t Afford’ Ozempic and Zepbound. What the Data on Healthier Patients and Cost Savings Actually Shows.
Insurers say the new weight-loss drugs are unaffordable. The data on healthier patients tells a more complicated story.